A systematic review of disparities in the medical management of atherosclerotic cardiovascular disease in females

IF 4.3 3区 材料科学 Q1 ENGINEERING, ELECTRICAL & ELECTRONIC ACS Applied Electronic Materials Pub Date : 2023-10-15 DOI:10.1053/j.semvascsurg.2023.10.005
Andrea Simioni , Jeniann A. Yi , Rabbia Imran , Anahita Dua
{"title":"A systematic review of disparities in the medical management of atherosclerotic cardiovascular disease in females","authors":"Andrea Simioni ,&nbsp;Jeniann A. Yi ,&nbsp;Rabbia Imran ,&nbsp;Anahita Dua","doi":"10.1053/j.semvascsurg.2023.10.005","DOIUrl":null,"url":null,"abstract":"<div><p><span><span>Atherosclerotic cardiovascular disease (ASCVD) is the leading cause of death in the United States and worldwide. Medical management of known modifiable risk factors, such as dyslipidemia<span>, hypertension, and diabetes, is a key aspect to its treatment. Unfortunately, there are substantial sex-based differences in the treatment of ASCVD that result in poor medical management and worse clinical outcomes. The objective of this </span></span>systematic review<span><span><span> was to summarize known disparities in the medical management of ASCVD in females. We included prior studies with specific sex- and sex-based analyses regarding the medical treatment of the following three major disease entities within ASCVD: </span>cerebrovascular disease<span><span>, coronary artery disease, and </span>peripheral artery disease. A total of 43 articles met inclusion criteria. In our analysis, we found that females were less likely to receive appropriate treatment of dyslipidemia or be prescribed </span></span>antithrombotic medications. However, treatment differences for diabetes and hypertension by sex were not as clearly represented in the included studies. In addition to rectifying these disparities in the medical management of ASCVD, this systematic review highlights the need to address larger issues, such as underrepresentation of females in </span></span>clinical trials, decreased access to care, and underdiagnosis of ASCVD to improve overall care for females.</p></div>","PeriodicalId":3,"journal":{"name":"ACS Applied Electronic Materials","volume":null,"pages":null},"PeriodicalIF":4.3000,"publicationDate":"2023-10-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"ACS Applied Electronic Materials","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0895796723000753","RegionNum":3,"RegionCategory":"材料科学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ENGINEERING, ELECTRICAL & ELECTRONIC","Score":null,"Total":0}
引用次数: 0

Abstract

Atherosclerotic cardiovascular disease (ASCVD) is the leading cause of death in the United States and worldwide. Medical management of known modifiable risk factors, such as dyslipidemia, hypertension, and diabetes, is a key aspect to its treatment. Unfortunately, there are substantial sex-based differences in the treatment of ASCVD that result in poor medical management and worse clinical outcomes. The objective of this systematic review was to summarize known disparities in the medical management of ASCVD in females. We included prior studies with specific sex- and sex-based analyses regarding the medical treatment of the following three major disease entities within ASCVD: cerebrovascular disease, coronary artery disease, and peripheral artery disease. A total of 43 articles met inclusion criteria. In our analysis, we found that females were less likely to receive appropriate treatment of dyslipidemia or be prescribed antithrombotic medications. However, treatment differences for diabetes and hypertension by sex were not as clearly represented in the included studies. In addition to rectifying these disparities in the medical management of ASCVD, this systematic review highlights the need to address larger issues, such as underrepresentation of females in clinical trials, decreased access to care, and underdiagnosis of ASCVD to improve overall care for females.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
对女性动脉粥样硬化性心血管疾病医疗管理差异的系统回顾
动脉粥样硬化性心血管疾病(ASCVD)是美国和世界范围内导致死亡的主要原因。医学管理已知的可改变的危险因素,如血脂异常,高血压和糖尿病是其治疗的关键方面。不幸的是,在ASCVD的治疗中存在显著的性别差异,导致医疗管理不善和临床结果较差。本系统综述的目的是总结女性ASCVD医学管理方面的已知差异。我们纳入了关于ASCVD中三种主要疾病实体(脑血管疾病、冠状动脉疾病和外周动脉疾病)的医学治疗的特定性别和基于性别的先前研究。共有43篇文章符合纳入标准。在我们的分析中,我们发现女性不太可能接受适当的血脂异常治疗或处方抗血栓药物。然而,在纳入的研究中,性别对糖尿病和高血压的治疗差异并没有明确的体现。除了纠正ASCVD医疗管理方面的这些差异外,本系统综述还强调需要解决更大的问题,如临床试验中女性代表性不足、获得护理机会减少和ASCVD诊断不足,以改善对女性的整体护理。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
CiteScore
7.20
自引率
4.30%
发文量
567
期刊最新文献
Hyperbaric oxygen treatment promotes tendon-bone interface healing in a rabbit model of rotator cuff tears. Oxygen-ozone therapy for myocardial ischemic stroke and cardiovascular disorders. Comparative study on the anti-inflammatory and protective effects of different oxygen therapy regimens on lipopolysaccharide-induced acute lung injury in mice. Heme oxygenase/carbon monoxide system and development of the heart. Hyperbaric oxygen for moderate-to-severe traumatic brain injury: outcomes 5-8 years after injury.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1